Cytidine 51-diphosphocholine (Citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28401-28417

  Roberti, Gloria ^a   Tanga, Lucia ^a   Michelessi, Manuele ^a   Quaranta, Luciano ^b   Parisi, Vincenzo ^a   Manni, Gianluca ^c   Oddone, Francesco ^a  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Citicoline; Glaucoma; Neuroprotection; Retinal ganglion cells

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINE ACETYLTRANSFERASE; CITICOLINE; EYE DROPS; LEVODOPA; NEUROTROPHIN 4; PROTEIN BCL 2; TYROSINE 3 MONOOXYGENASE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; AMBLYOPIA; BARTHEL INDEX; BRAIN ISCHEMIA; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; GLAUCOMA; HUMAN; IMMUNOREACTIVITY; INTRAOCULAR PRESSURE; ISCHEMIC OPTIC NEUROPATHY; LATERAL GENICULATE BODY; MITOCHONDRIAL ENERGY TRANSFER; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NERVE; OUTCOME ASSESSMENT; PARKINSON DISEASE; RETINA GANGLION CELL; REVIEW; TUNEL ASSAY; VISUAL ACUITY; VISUAL FIELD DEFECT; ANIMAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY; DRUG EFFECTS; EYE; METABOLISM;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CYTIDINE DIPHOSPHATE CHOLINE; EYE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS; OPHTHALMIC SOLUTIONS; RETINAL GANGLION CELLS;

EID: 84949008742     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226099     Document Type: Review

References (83)

1. De la Morena, E.; Goldberg, D.M.; Werner, M. Citidín difosfato de colina y biosíntesis de fosfolípidos. In Citicolina: Bioquímica, Neurofarmacología y Clínica; De la Morena, E., Ed.; Salvat: Barcelona, Spain, 1985; pp. 25-38.
2. Saver, J.L. Citicoline: Update on a promising and widely available agent for neuroprotection and neurorepair. Rev. Neurol. Dis. 2008, 5, 167-177. [PubMed]
3. Fagone, P.; Jackowski, S. Phosphatidylcholine and the CDP-choline cycle. Biochim. Biophys. Acta 2013, 1831, 523-532. [CrossRef] [PubMed]
4. Secades, J.J. Citicoline: Pharmacological and clinical review, 2010 update. Rev. Neurol. 2011, 52, S1-S62. [PubMed]
5. Rao, A.M.; Hatcher, J.F.; Dempsey, R.J. Does CDP-choline modulate phospholipase activities aftertransient forebrain ischemia? Brain Res. 2001, 893, 268-272. [CrossRef]
6. Martinet, M.; Fonlupt, P.; Pacheco, H. Effects of cytidine-5′-diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch. Int. Pharmacodyn. Ther. 1979, 239, 52-61. [PubMed]
7. Skripuletz, T.; Manzel, A.; Gropengießer, K.; Schäfer, N.; Gudi, V.; Singh, V.; Salinas Tejedor, L.; Jörg, S.; Hammer, A.; Voss, E.; et al. Pivotal role of choline metabolites in remyelination. Brain 2015, 138, 398-413. [CrossRef] [PubMed]
8. Schauss, A.G.; Somfai-Relle, S.; Financsek, I.; Glavits, R.; Parent, S.C.; Endres, J.R.; Varga, T.; Szücs, Z.; Clewell, A. Single- and repeated-dose oral toxicity studies of citicoline free-base (choline cytidine 5′-pyrophosphate) in Sprague-Dawley rats. Int. J. Toxicol. 2009, 28, 479-487. [CrossRef] [PubMed]
9. Lozano, F.R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung 1983, 33, 1073-1080.
10. Grieb, P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs 2014, 28, 185-193. [CrossRef] [PubMed]
11. Grieb, P.; Rejdak, R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J. Neurosci. Res. 2002, 67, 143-148. [CrossRef] [PubMed]
12. Alvarez-Sabín, J.; Román, G.C. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013, 3, 1395-1414. [CrossRef] [PubMed]
13. Gutiérrez-Fernández, M.; Rodríguez-Frutos, B.; Fuentes, B.; Vallejo-Cremades, M.T.; Alvarez-Grech, J.; Expósito-Alcaide, M.; Díez-Tejedor, E. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem. Int. 2012, 60, 310-317. [CrossRef] [PubMed]
14. Dávalos, A.; Alvarez-Sabín, J.; Castillo, J.; Díez-Tejedor, E.; Ferro, J.; Martínez-Vila, E.; Serena, J.; Segura, T.; Cruz, V.T.; Masjuan, J.; et al. Citicoline in the treatment of acute ischaemic stroke: An international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012, 380, 349-357. [CrossRef]
15. Overgaard, K. The effects of citicoline on acute ischemic stroke: A review. J. Stroke Cerebrovasc. Dis. 2014, 23, 1764-1769. [CrossRef] [PubMed]
16. Cacabelos, R.; Caamaño, J.; Gómez, M.J.; Fernández-Novoa, L.; Franco-Maside, A.; Alvarez, X.A. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann. N. Y. Acad. Sci. 1996, 777, 399-403. [CrossRef] [PubMed]
17. Alvarez, X.A.; Sampedro, C.; Lozano, R.; Cacabelos, R. Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Methods Find Exp. Clin. Pharmacol. 1999, 21, 535-540. [CrossRef] [PubMed]
18. Yang, X.; Sheng, W.; He, Y.; Cui, J.; Haidekker, M.A.; Sun, G.Y.; Lee, J.C.-M. Secretory phospholipase A2 type III enhances αsecretase-dependent amyloid precursor protein processing through alterations in membrane fluidity. J. Lipid Res. 2010, 51, 957-966. [CrossRef] [PubMed]
19. Brender, J.R.; Lee, E.L.; Cavitt, M.A.; Gafni, A.; Steel, D.G.; Ramamoorthy, A. Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide. J. Am. Chem. Soc. 2008, 130, 6424-6429. [CrossRef] [PubMed]
20. Alvarez, X.A.; Mouzo, R.; Pichel, V.; Pérez, P.; Laredo, M.; Fernández-Novoa, L.; Corzo, L.; Zas, R.; Alcaraz, M.; Secades, J.J.; et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp. Clin. Pharmacol. 1999, 21, 633-644. [PubMed]
21. Franco-Maside, A.; Caamaño, J.; Gómez, M.J.; Cacabelos, R. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease. Methods Find Exp. Clin. Pharmacol. 1994, 16, 597-607. [PubMed]
22. Fioravanti, M.; Yanagi, M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst. Rev. 2005, 18, CD000269. [CrossRef]
23. Agnoli, A.; Ruggieri, S.; Denaro, A.; Bruno, G. New strategies in the management of Parkinson's disease: A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 1982, 8, 289-296. [CrossRef] [PubMed]
24. Saligaut, C.; Daoust, M.; Moore, N.; Boismare, F. Circling behaviour in rats with unilateral lesions of the nigrostriatum induced by 6-hydroxydopamine: Changes induced by oral administration of cytidine-5′-diphosphocholine. Neuropharmacology 1987, 26, 1315-1319. [CrossRef]
25. Eberhardt, R.; Birbamer, G.; Gerstenbrand, F.; Rainer, E.; Traegner, H. Citicoline in the treatment of Parkinson's disease. Clin. Ther. 1990, 12, 489-495. [PubMed]
26. Campos, E.C.; Bolzani, R.; Schiavi, C.; Baldi, A.; Porciatti, V. Cytidin-5′-diphosphocholine enhances the effect of part-time occlusion in amblyopia. Doc. Ophthalmol. 1996-1997, 93, 247-263. [CrossRef]
27. Fresina, M.; Dickmann, A.; Salerni, A.; de Gregorio, F.; Campos, E.C. Effect of oral CDP-choline on visual function in young amblyopic patients. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246, 143-150. [CrossRef] [PubMed]
28. Pawar, P.V.; Mumbare, S.S.; Patil, M.S.; Ramakrishnan, S. Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: A randomized controlled trial. Indian J. Ophthalmol. 2014, 62, 124-129. [CrossRef] [PubMed]
29. Porciatti, V.; Schiavi, C.; Benedetti, P.; Baldi, A.; Campos, E.C. Cytidine-5′-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr. Eye Res. 1998, 17, 141-148. [CrossRef] [PubMed]
30. Parisi, V.; Coppola, G.; Ziccardi, L.; Gallinaro, G.; Falsini, B. Cytidine-5′-diphosphocholine (Citicoline): A pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur. J. Neurol. 2008, 15, 465-474. [CrossRef] [PubMed]
31. Weinreb, R.N.; Aung, T.; Medeiros, F.A. The pathophysiology and treatment of glaucoma: A review. JAMA 2014, 311, 1901-1911. [CrossRef] [PubMed]
32. Tham, Y.C.; Li, X.; Wong, T.Y.; Quigley, H.A.; Aung, T.; Cheng, C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 2014, 121, 2081-2890. [CrossRef] [PubMed]
33. Gordon, M.O.; Beiser, J.A.; Brandt, J.D.; Heuer, D.K.; Higginbotham, E.J.; Johnson, C.A.; Keltner, J.L.; Miller, J.P.; Parrish, R.K., 2nd;Wilson, M.R.; et al. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002, 120, 714-720. [CrossRef] [PubMed]
34. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 1998, 126, 487-497.
35. Heijl, A.; Leske, M.C.; Bengtsson, B.; Hyman, L.; Bengtsson, B.; Hussein, M.; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002, 120, 1268-1279. [CrossRef] [PubMed]
36. Kass, M.A.; Heuer, D.K.; Higginbotham, E.J.; Johnson, C.A.; Keltner, J.L.; Miller, J.P.; Parrish, R.K., 2nd; Wilson, M.R.; Gordon, M.O. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002, 120, 701-713. [CrossRef] [PubMed]
37. American Academy of Ophthalmology (AAO). Primary angle closure glaucoma. In Preferred Practice Patterns Guidelines; American Academy of Opthalmology: San Francisco, CA, USA, 2010.
38. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 4th ed.; Publicomm: Savona, Italy, 2014.
39. Gupta, N.; Ang, L.C.; Noël de Tilly, L.; Bidaisee, L.; Yücel, Y.H. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br. J. Ophthalmol. 2006, 90, 674-678. [CrossRef] [PubMed]
40. Weber, A.J.; Chen, H.; Hubbard, W.C.; Kaufman, P.L. Experimental glaucoma and cell size, density, and number in the primate lateral geniculate nucleus. Investig. Ophthalmol. Vis. Sci. 2000, 41, 1370-1379.
41. Yücel, Y.H.; Zhang, Q.;Weinreb, R.N.; Kaufman, P.L.; Gupta, N. Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Investig. Ophthalmol. Vis. Sci. 2001, 42, 3216-3222.
42. Schumer, R.A.; Podos, S.M. The nerve of glaucoma! Arch. Ophthalmol. 1994, 112, 37-44. [CrossRef] [PubMed]
43. Buckingham, B.P.; Inman, D.M.; Lambert, W.; Oglesby, E.; Calkins, D.J.; Steele, M.R.; Vetter, M.L.; Marsh-Armstrong, N.; Horner, P.J. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J. Neurosci. 2008, 28, 2735-2744. [CrossRef] [PubMed]
44. Tamm, E.R.; Schmetterer, L.; Grehn, F. Status and perspectives of neuroprotective therapies in glaucoma: The European Glaucoma Society White Paper. Cell Tissue Res. 2013, 353, 347-354. [CrossRef] [PubMed]
45. Nickells, R.W. Retinal ganglion cell death in glaucoma: The how, the why, and the maybe. J. Glaucoma 1996, 5, 345-356. [CrossRef] [PubMed]
46. Corredor, R.G.; Goldberg, J.L. Electrical activity enhances neuronal survival and regeneration. J. Neural Eng. 2009, 6, 055001. [CrossRef] [PubMed]
47. Weinreb, R.N. Glaucoma neuroprotection: What is it? Why is it needed? Can. J. Ophthalmol. 2007, 42, 396-398. [CrossRef] [PubMed]
48. Weinreb, R.N.; Levin, L.A. Is neuroprotection a viable therapy for glaucoma? Arch. Ophthalmol. 1999, 117, 1540-1544. [CrossRef] [PubMed]
49. Rudzinski, M.; Wong, T.P.; Saragovi, H.U. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J. Neurobiol. 2004, 58, 341-354. [CrossRef] [PubMed]
50. Hayreh, S.S.; March, W.; Anderson, D.R. Pathogenesis of block of rapid orthograde axonal transport by elevated intraocular pressure. Exp. Eye Res. 1979, 28, 515-523. [CrossRef]
51. Quigley, H.A.; McKinnon, S.J.; Zack, D.J.; Pease, M.E.; Kerrigan-Baumrind, L.A.; Kerrigan, D.F.; Mitchell, R.S. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Investig. Ophthalmol. Vis. Sci. 2000, 41, 3460-3466.
52. Colafrancesco, V.; Parisi, V.; Sposato, V.; Rossi, S.; Russo, M.A.; Coassin, M.; Lambiase, A.; Aloe, L. Ocular application of nerve growth factor protects degenerating retinal ganglion cells in a rat model of glaucoma. J. Glaucoma 2011, 20, 100-108. [CrossRef] [PubMed]
53. Pease, M.E.; Zack, D.J.; Berlinicke, C.; Bloom, K.; Cone, F.; Wang, Y.; Klein, R.L.; Hauswirth, W.W.; Quigley, H.A. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Investig. Ophthalmol. Vis. Sci. 2009, 50, 2194-200. [CrossRef] [PubMed]
54. Lipton, S.A.; Rosenberg, P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994, 330, 613-622. [PubMed]
55. Guo, L.; Salt, T.E.; Maass, A.; Luong, V.; Moss, S.E.; Fitzke, F.W.; Cordeiro, M.F. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Investig. Ophthalmol. Vis. Sci. 2006, 47, 626-633. [CrossRef] [PubMed]
56. Baltmr, A.; Duggan, J.; Nizari, S.; Salt, T.E.; Cordeiro, M.F. Neuroprotection in glaucoma-Is there a future role? Exp. Eye Res. 2010, 91, 554-566. [CrossRef] [PubMed]
57. Cheung,W.; Guo, L.; Cordeiro, M.F. Neuroprotection in glaucoma: Drug-based approaches. Optom. Vis. Sci. 2008, 85, 406-416. [CrossRef] [PubMed]
58. Payne, A.J.; Kaja, S.; Sabates, N.R.; Koulen, P. Neuroprotection in eye disease: Developments in translational research. Mo Med. 2013, 110, 429-436. [PubMed]
59. Prokai-Tatrai, K.; Xin, H.; Nguyen, V.; Szarka, S.; Blazics, B.; Prokai, L.; Koulen, P. 17β-Estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma. Mol. Pharm. 2013, 10, 3253-3261. [CrossRef] [PubMed]
60. Areosa, S.A.; Sherriff, F. Memantine for dementia. Cochrane Database Syst. Rev. 2003, 3, CD003154. [CrossRef] [PubMed]
61. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994, 330, 585-591. [CrossRef] [PubMed]
62. Rejdak, R.; Toczolowski, J.; Solski, J.; Duma, D.; Grieb, P. Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Res. 2002, 34, 146-149. [CrossRef] [PubMed]
63. Oshitari, T.; Fujimoto, N.; Adachi-Usami, E. Citicoline has a protective effect on damaged retinal ganglion cells in mouse culture retina. Neuroreport 2002, 13, 2109-2111. [CrossRef] [PubMed]
64. Schuettauf, F.; Rejdak, R.; Thaler, S.; Bolz, S.; Lehaci, C.; Mankowska, A.; Zarnowski, T.; Junemann, A.; Zagorski, Z.; Zrenner, E.; et al. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. Exp. Eye Res. 2006, 83, 1128-1134. [CrossRef] [PubMed]
65. Park, C.H.; Kim, Y.S.; Noh, H.S.; Cheon, E.W.; Yang, Y.A.; Yoo, J.M.; Choi,W.S.; Cho, G.J. Neuroprotective effect of citicoline against KA-induced neurotoxicity in the rat retina. Exp. Eye Res. 2005, 81, 350-358. [CrossRef] [PubMed]
66. Matteucci, A.; Varano, M.; Gaddini, L.; Mallozzi, C.; Villa, M.; Pricci, F.; Malchiodi-Abedi, F. Neuroprotective effects of citicoline in in vitro models of retinal neurodegeneration. Int. J. Mol. Sci. 2014, 15, 6286-6297. [CrossRef] [PubMed]
67. Zerbini, G.; Bandello, F.; Lattanzio, R.; Gabellini, D.; Zucchiatti, I.; Spinello, A.; Capuano, V.; Preziosa, C.; Maestroni, S. In vivo evaluation of retinal and choroidal structure in a mouse model of long-lasting diabetes. Effect of topical treatment with citicoline. J. Ocul. Dis. Ther. 2015, 3, 1-8. [CrossRef]
68. Oshitari, T.; Yoshida-Hata, N.; Yamamoto, S. Effect of neurotrophic factors on neuronal apoptosis and neurite regeneration in cultured rat retinas exposed to high glucose. Brain Res. 2010, 1346, 43-51. [CrossRef] [PubMed]
69. Pecori Giraldi, J.; Virno, M.; Covelli, G.; Grechi, G.; de Greforio, F. Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int. Ophthalmol. 1989, 13, 109-112. [CrossRef] [PubMed]
70. Virno, M.; Pecori-Giraldi, J.; Liguori, A.; de Gregorio, F. The protective effect of Citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow up). Acta Ophthalmol. Scand. 2000, 232, 56-57. [CrossRef]
71. Parisi, V.; Manni, G.; Colacino, G.; Bucci, M.G. Cytidine-5′-diphpsphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999, 106, 1126-1134. [CrossRef]
72. Parisi, V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5′-diphosphocholine (citicoline): A study of 8 years of follow-up. Doc. Ophthalmol. 2005, 110, 91-102. [CrossRef] [PubMed]
73. Rejdak, R.; Toczolowski, J.; Krukowski, J.; Kaminski, M.; Rejdak, K.; Stelmasiak, Z.; Grieb, P. Oral citicoline treatment improves visual pathway function in glaucoma. Med. Sci. Monit. 2003, 9, PI24-PI28. [PubMed]
74. Parisi, V.; Coppola, G.; Centofanti, M.; Oddone, F.; Angrisani, A.M.; Ziccardi, L.; Ricci, B.; Quaranta, L.; Manni, G. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog. Brain Res. 2008, 173, 541-554. [PubMed]
75. Ottobelli, L.; Manni, G.L.; Centofanti, M.; Iester, M.; Allevena, F.; Rossetti, L. Citicoline oral solution in glaucoma: Is there a role in slowing disease progression? Ophthalmologica 2013, 29, 219-226. [CrossRef] [PubMed]
76. 14C]-Cytidine Diphosphocholine. Curr. Ther. Res. 1983, 34, 1049-1053.
77. 14C CDP-Choline by Oral Route. Arzneimittelforschung 1983, 33, 1045-1047. [PubMed]
78. Roberti, G.; Tanga, L.; Parisi, V.; Sampalmieri, M.; Centofanti, M.; Manni, G. A preliminary study of the neuroprotective role of Citicoline eye drops in glaucomatous optic neuropathy. Indian J. Ophthalmol. 2014, 62, 549-553. [CrossRef] [PubMed]
79. Parisi, V.; Centofanti, M.; Ziccardi, L.; Tanga, L.; Michelessi, M.; Roberti, G.; Manni, G. Treatment with Citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 2015, 253, 1327-1340. [CrossRef] [PubMed]
80. Chang, E.E.; Goldberg, J.L. Glaucoma 2.0: Neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 2012, 119, 979-986. [CrossRef] [PubMed]
81. Goldberg, J.L. The optic nerve. In Adler's Physiology of the Eye, 11th ed.; Levin, L.A., Nilsson, S.F., Ver Hoeve, J., Wu, S., Kaufman, P.L., Alm, A., Eds.; Saunders/Elsevier: New York, NY, USA, 2011.
82. Fredette, M.J.; Anderson, D.R.; Porciatti, V.; Feuer, W. Reproducibility of pattern electroretinogram in glaucoma patients with a range of severity of disease with the new glaucoma paradigm. Ophthalmology 2008, 115, 957-963. [CrossRef] [PubMed]
83. Quigley, H.A. Clinical trials for glaucoma neuroprotection are not impossible. Curr. Opin. Ophthalmol. 2012, 23, 144-154. [CrossRef] [PubMed]